All articles tagged with #novartis
Rival drugmakers, led by Novartis, are sprinting to prove that lowering Lp(a) — a genetic risk factor affecting about 1 in 5 people — can prevent heart disease, a space with no approved therapies and a potential multi‑billion market as late-stage trials seek to show fewer cardiovascular events.
Novartis will acquire Excellergy for up to USD 2 billion in upfront and milestone payments to bolster its immunology portfolio with Exl-111, a Phase 1, half-life–extended anti-IgE antibody designed to dissociate receptor-bound IgE and drive faster, deeper IgE signaling suppression. If approved, Exl-111 could improve symptom control and dosing convenience across IgE‑driven diseases such as food allergy, chronic urticaria, inducible urticaria and asthma; closing is targeted for H2 2026, subject to regulatory approvals.
Novartis today announced plans to acquire SNV4818 from Synnovation Therapeutics' Pikavation subsidiary for up to USD 3 billion (USD 2 billion upfront with up to USD 1 billion in milestones) to advance a pan-mutant‑selective PI3Kα inhibitor in HR+/HER2- breast cancer; SNV4818 is designed to target mutant PI3Kα (PIK3CA) while sparing wild-type PI3Kα to improve tolerability and enable combination with hormonal therapies, addressing an unmet need in roughly 40% of HR+/HER2- patients; closing is expected in the first half of 2026.
Henrietta Lacks’ estate has scored another legal win in the decades-long fight over the unauthorized use of her immortal HeLa cells, with recent settlements against major pharma firms following earlier deals (including Thermo Fisher) and ongoing discussions about patient consent and exploitation in medical research.
Atrium Therapeutics, a spinout formed from Novartis's $12 billion acquisition of Avidity Biosciences, debuts with $270 million in cash and two preclinical RNA interference assets (ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy). Led by Kathleen Gallagher, Atrium plans a Phase 1 trial for ATR 1072 in the second half of this year and for ATR 1086 in 2027, with the new ticker RNAM, inheriting Avidity's market position.
The family of Henrietta Lacks has reached a second confidential settlement with Novartis over profits from her immortal HeLa cells, continuing a long fight for compensation; terms are undisclosed and follow a prior settlement with Thermo Fisher, underscoring ongoing ethical questions about consent and the benefits derived from her cells.
Novartis has reached a settlement with Henrietta Lacks' estate over the use of her HeLa cells in medical research, ending a dispute with undisclosed terms; the case highlights ongoing debates about consent and compensation tied to the iconic cell line used in biomedical advances since 1951.
WHO renews its commitment to a leprosy-free world ahead of World Leprosy Day, highlighting free multidrug therapy and post-exposure prophylaxis, a 25-year partnership with novartis, and ongoing anti-stigma efforts, while noting 172,717 new cases in 2024 across 188 reporting areas.
A Seeking Alpha roundup features Ray Dalio warning that Trump's aggressive foreign policy could deter foreign investors from U.S. assets, Amazon noting tariffs are lifting some prices and slowing inventory turnover, and Novartis stating its U.S. investments and trade deals should shield it from most tariffs with contingency plans in place.
Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.
Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.
Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.
Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.
Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.
Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.